StockData
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA) company profile

KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.51+0.08 (+17.64%)

Close on Nov 18, 2026Market cap $17.07MP/E –Yield –

About Pasithea Therapeutics

Pharmaceutical Preparations, SIC 2834

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company engaged in discovering, researching, and developing therapeutic treatments. Its drug development pipeline primarily focuses on small molecule therapies for RASopathies, tumors driven by the MAPK pathway, and central nervous system disorders. The company's lead therapeutic product candidate is PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor being evaluated for advanced solid tumors and neurofibromatosis type 1, including plexiform neurofibromas. Additionally, the company conducts early-stage research on its PAS-001 program, which targets complement component 4A for schizophrenia.

As a clinical-stage development enterprise, the company does not operate commercial sales facilities and aims to develop treatments for patients with high unmet medical needs. Clinical trials for its lead drug candidate take place across multiple international locations, including study sites in the United States, Eastern Europe, Australia, and South Korea. Pasithea Therapeutics Corp. is incorporated in Delaware and maintains its principal executive offices in Miami Beach, Florida.

Summary of the business section of Pasithea Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Pasithea Therapeutics Corp.
Headquarters
Miami Beach, FL
Address
1111 Lincoln Road, Suite 500 33139
Phone
(702) 514-4174
Employees
5, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C., Hartford, Connecticut

Stock & identifiers

Ticker
KTTA
Exchange
Nasdaq
IPO date
Sep 16, 2021
Shares outstanding
33M, Aug 12, 2026
Public float
$5.10M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-20 reverse, Jan 2, 2024
SEC CIK
1841330
CUSIP
70261F202
ISIN
US70261F2020
FIGI
BBG01018ZGY8
Share class FIGI
BBG01018ZHS3
EIN
85-1591963

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Tiago MarquesChief Executive Officer, Director73,334
Kartik KrishnanChief Medical Officer–
Daniel H. SchneidermanChief Financial Officer26,667
Simon DumesnilDirector35,833
Lawrence SteinmanDirector199,691
Alfred J. NovakDirector3,500
Emer LeahyDirector33,333

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Tiago Reis Marques
Chief Executive Officer
$533.61K$493.15K$277.26K$23.50K$1.33M+107%
Daniel Schneiderman
Chief Financial Officer
$386.98K$306.40K$178.30K$23.50K$895.19K+108%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 16, 2021
Offer price
$5.00
Securities offered
4,800,000
Gross proceeds
$24.00M
Exchange
Nasdaq
First trading day
Sep 15, 2021
First-day close
$3.56-28.8%
Lock-up ends (est.)
Mar 14, 2022

“The initial public offering price of our Unit is $5.00 per Unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had five full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?